At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Neoadjuvant, Randomized, Phase II Study of Vascular Endothelial Growth Factor (VEGF) Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
In Brief
A Phase 2 clinical trial evaluating Pazopanib and Placebo for Adenocarcinoma of the Prostate. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The area around a tumor ("pre-metastatic niche") may be an area to which cancer cells are attracted. The study doctor will take blood and tumor samples to look for certain features linked with response to treatment so that they can predict which future patients may benefit from this therapy. The purpose of this study is to see if the drug pazopanib can be used to reduce the amount of pre-metastatic niche in the patient's lymph nodes (a common site for prostate cancer to spread). Down the line, this may help to prevent prostate cancer from coming back after surgery.
Study Details
Timeline
Interventions
Pazopanib, 800 mg, orally daily for 28 days prior to radical prostatectomy.
Placebo tablet orally, daily for 28 days prior to radical prostatectomy.